Navigation Links
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Date:11/7/2013

delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) acceptance, review and approval decisions for new drug applications by health authorities is an uncertain and evolving process and health authorities retain significant discretion at all stages of the regulatory review and approval decision process; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (v) patents may not issue from our patent applications our proprietary or partnered drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; (vi) the outcome of any existing or future intellectual property or other litigation related to our proprietary or partnered drug candidates; and (vii) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q to be filed with the Securities and Exchange Commission on November 7, 2013. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Nektar Investor Inquiries: Jennifer Ruddock/Nektar Therapeutics

(415) 482-5585Susan Noonan/SA Noonan Communications, LLC 

(212)
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MILFORD, Pa. , Sept. 17, 2014  Fortune ... has officially changed its name to Manzo Pharmaceuticals, Inc. ... change to take effect today, September 17, 2014. Also ... split. The approval is a pivotal event ... Manzo . Mr. Manzo explained, "We could not proceed ...
(Date:9/17/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a ... an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ... outstanding shares of Auxilium common stock at a price ... subject to due diligence, financing and other conditions. A ... from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... -- Mindray (NYSE: MR)announced its new generation DC-70 ultrasound ... been showcased for the first time at ISUOG in ... is scheduled for availability in the U.S. market in ... efficient workhorse in the mid-range segment, the DC-70 combines ... user experience including a gesture-sensitive touch screen, delivering accurate ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
... July 29 Micromet, Inc.,(Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune,diseases, today announced ... audio,webcast on Thursday, August 7, 2008, at 9:00 ... discuss its second quarter 2008 financial,results. Micromet anticipates ...
... July 28 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... study of intravenous (i.v.) peramivir administered via a ... treatment of seasonal,influenza. The trial, conducted by BioCryst,s ... primary endpoint of improvement in the median time ...
Cached Medicine Technology:Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 4BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 5
(Date:9/17/2014)... By Steven Reinberg ... -- On the same day that President Barack Obama announced ... Africa,s Ebola crisis, the World Health Organization warned Tuesday that ... infections could start doubling every three weeks. Obama said ... offer medical and logistical support to beleaguered health care facilities ...
(Date:9/17/2014)... severe maternal morbidity amongst women in Australia is ... study published today (17 September) in BJOG: ... , Australians generally enjoy high standards of living; ... exist, in particular between indigenous and non indigenous ... the independent impact of socioeconomic position on severe ...
(Date:9/17/2014)... of a perfectly poured glass of wine leads to an ... Denmark, have now developed a nanosensor that can mimic what ... measures how you experience the sensation of dryness in the ... they need to control a number of processes to bring ... in the wine bottle. An important part of the taste ...
(Date:9/17/2014)... 17, 2014 MarijuanaStock.net, a cannabis ... recently launched a “Video” section that contains important ... in the marijuana industry made available in video ... visitor is given access to numerous interviews, news ... businesses and the issues they face. , ...
(Date:9/17/2014)... Fresh off their High Times Cannabis ... support of The Silver Tour, an educational non-profit effort ... benefits of medical marijuana. , Florida Buds, a Florida ... marijuana dispensary and treatment center, donated $1,000.00 to ... launch a statewide radio campaign in advance of Election ...
Breaking Medicine News(10 mins):Health News:Obama Steps Up Aid to Fight Ebola in West Africa 2Health News:Obama Steps Up Aid to Fight Ebola in West Africa 3Health News:New study examines the impact of socioeconomic position and maternal morbidity in Australia 2Health News:New study examines the impact of socioeconomic position and maternal morbidity in Australia 3Health News:Nanoscience makes your wine better 2Health News:Nanoscience makes your wine better 3Health News:MarijuanaStock.net Adds Business News Video Section to Their Website 2Health News:Florida Buds Supports Silver Tour 2
... low for people who suffer from traumatic brain injury ... function. TBI can impair a patient,s mental abilities, impact ... And long-term medical treatment carries a high economic cost. ... Air Force, Prof. Chaim Pick of Tel Aviv University,s ...
... , This release is available in German ... Foundation) is to establish 20 Collaborative Research Centres (CRCs) by ... Committee at its spring session in Bonn. The new CRCs ... percent programme allowance for indirect project costs) for the initial ...
... not won in a single battle: Long after a cancer has ... is under debate, and much is unclear. New research led by ... blood cancer, the source of cancer recurrence is in a set ... cells, and thus able to survive chemotherapy. The findings, which appeared ...
... TUESDAY, May 29 (HealthDay News) -- People with less than ... problems with their thinking skills later in life, according to ... researchers from Harvard University noted that people with more education ... thinking, or so-called "cognitive," skills, even if they had the ...
... Dotinga HealthDay Reporter , MONDAY, May 28 (HealthDay ... pounds because her friends sit around? A small study ... after-school programs if they hung out with active kids, and ... that friends directly affect how active kids are, and it,s ...
... treatment for suspected HIV is critical, pre-exposure preventive treatment ... people in high-risk groups, states a review of evidence ... "Although postexposure prophylaxis has a long history of ... treatment in the course of infection ("treatment as prevention") ...
Cached Medicine News:Health News:Diabetes drug could be a promising therapy for traumatic brain injury 2Health News:Diabetes drug could be a promising therapy for traumatic brain injury 3Health News:DFG establishes 20 new Collaborative Research Centres 2Health News:DFG establishes 20 new Collaborative Research Centres 3Health News:DFG establishes 20 new Collaborative Research Centres 4Health News:DFG establishes 20 new Collaborative Research Centres 5Health News:DFG establishes 20 new Collaborative Research Centres 6Health News:Why chemotherapy fails 2Health News:Why chemotherapy fails 3Health News:Education May Protect Brain From Exposure to Solvents 2Health News:Key to More Active, Slimmer Kids: Friends 2Health News:Antiretroviral treatment for preventing HIV infection: an evidence review for physicians 2
... Gemini is the newest addition to Laserscopes ... distinct wavelengths to choose from, 1064nm Nd:YAG ... in an exploding non-invasive aesthetic laser market ... and effectiveness while maintaining the safety and ...
... Surgical Laser System is designed for ... high-power, dual-wavelength system designed for urology, ... surgery, neurosurgery, pulmonary surgery and gastroenterology ... vaporizes and coagulates tissue with minimal ...
... biolitecs Ceralas D 980 nm diode laser ... bloodless field for most surgical procedures. ... cuts optically without collateral tissue damage ... coagulates blood instantly and seals small blood ...
... is a monoclonal antibody based ... confirmatory identification of Neisseria gonorrhoeae. ... isolated, viable or fresh cultures. ... two minute rotation, a positive ...
Medicine Products: